Avenzoar Pharmaceuticals

Executive Summary

Avenzoar Pharmaceuticals is a pre-clinical biotech company pioneering small molecule therapeutics to address cancer metastasis and drug resistance, two major drivers of mortality in recalcitrant cancers such as pancreatic and ovarian cancer. Founded in 2020 and headquartered in San Diego, the company leverages an AI-enabled precision oncology platform to accelerate drug discovery and identify novel targets, with the goal of personalizing therapy for patients who have limited treatment options. The platform integrates computational biology and machine learning to optimize lead compounds, potentially improving the efficacy and safety profiles of its pipeline candidates. Currently in the pre-clinical stage, Avenzoar is advancing its lead program toward IND-enabling studies. The company's focus on high-unmet-need indications positions it for significant impact if its platform successfully translates into clinical candidates. Key near-term milestones include demonstrating in vivo proof-of-concept, completing IND-enabling toxicology, and securing additional funding to advance into clinical trials. While still early-stage, Avenzoar's AI-driven approach and strategic focus on metastatic and resistant cancers provide a differentiated value proposition in the competitive oncology landscape.

Upcoming Catalysts (preview)

• Q2 2027IND Filing for Lead Candidate40% success
• Q2 2026Preclinical Data Presentation at Major Conference70% success
• Q4 2026Series A Financing Announcement60% success